China Healthcare "Expert call takeaways: In vivo CAR-T intro and cell th..."

Research evidence excerpt

China Healthcare "Expert call takeaways: In vivo CAR-T intro and cell th..."

Global Research

13 May 2026ab

China Healthcare Equities

ChinaExpert call takeaways: In vivo CAR-T intro and

cell therapy market update Healthcare

Anita Wei

Analyst

anita.wei@ubs.com

Key topics from the expert call +852-2971 7459

On 12 May, we invited Mr. Kong, Director of Clinical Operations at Starna Therapeutics, Liz Han, CFA

to share his insights into CAR-T industry trends. Key topics included: 1) the advantages Analyst

and challenges of in vivo CAR-T technology, and how its two delivery systems differ from liz.han@ubs.com

each other, 2) the outlook for in vivo CAR-T business development (BD) in China; and 3) +852-2971 6106

sales trends for CAR-T products since their inclusion in the commercial insurance drug Chen Chen, PhD

list (CIDL). Analyst

S1460520100001

In vivo CAR-T: lower cost and greater efficiency than traditional CAR-T chen-zb.chen@ubs.com

As an emerging, still-developing technology, in vivo CAR-T offers potential advantages +86-10-5832 8201

in both cost and efficiency compared with traditional ex vivo CAR-T. By engineering a

patient’s T cells directly within the body, in vivo CAR-T eliminates the need for complex,

costly and time-consuming ex vivo manufacturing. According to the expert, large scale

industrial production could reduce manufacturing costs to hundreds of US dollars per

vial. In China, most in vivo CAR-T programmes are currently conducted under

investigator-initiated trials (IITs), with a lack of robust late-stage clinical validation.

Current development is concentrated in oncology and autoimmune diseases, focusing

on validated targets such as CD19 and BCMA. There are two mainstream delivery

systems: viral vectors and LNP-mRNA.